Enveric Biosciences Inc
Change company Symbol lookup
Select an option...
ENVB Enveric Biosciences Inc
AHI Advanced Health Intelligence Ltd
OTLK Outlook Therapeutics Inc
PBHC Pathfinder Bancorp Inc (MARYLAND)
CMA Comerica Inc
IART Integra Lifesciences Holdings Corp
ARKW.SO ARK Next Generation Internet ETF
AGNC Agnc Investment Corp
HCA HCA Healthcare Inc
LGHL Lion Group Holding Ltd
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.

Postmarket

Last Trade
Delayed
$2.55
0.01 (0.39%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$2.54
Day's Change
-0.16 (-5.93%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
2.71
Day's Low
2.26
Volume
(Below Average)
Volume:
34,646

10-day average volume:
42,395
34,646

Company Profile

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.19x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2023
Current Month
24.2K
Previous Month
44.2K
Percent of Float
1.25%
Days to Cover
0.8269 Days

Share Information

ENVB is in a share class of common stock
Float
1.9M
Shares Outstanding
2.2M
Institutions Holding Shares
12
8.56%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • David Ian JohnsonChmn.
  • Joseph TuckerCEO
  • Kevin M. CoveneyCFO
  • Bob DagherOther
  • Peter FacchiniOther

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.